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Mass cytometry reveals cellular fingerprint
associated with IgE+ peanut tolerance and allergy
in early life
Melanie R. Neeland 1,2,7✉, Sandra Andorf 3,4,5,7, Monali Manohar3, Diane Dunham3, Shu-Chen Lyu3,
Thanh D. Dang1,2, Rachel L. Peters1,2, Kirsten P. Perrett1,6, Mimi L.K. Tang 1,2, Richard Saffery 1,2,
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IgE-mediated peanut allergic is common, often serious, and usually lifelong. Not all individuals
who produce peanut-specific IgE will react upon consumption of peanut and can eat the food
without adverse reactions, known as sensitized tolerance. Here, we employ high-dimensional
mass cytometry to define the circulating immune cell signatures associated with sensitized
tolerance and clinical allergy to peanut in the first year of life. Key features of clinical peanut
allergic are increased frequency of activated B cells (CD19hiHLADRhi), overproduction of
TNFα and increased frequency of peanut-specific memory CD4 T cells. Infants with sensi-
tized tolerance display reduced frequency but hyper-responsive naive CD4 T cells and an
increased frequency of plasmacytoid dendritic cells. This work demonstrates the utility and
power of high-dimensional mass cytometry analysis to interrogate the cellular interactions
that are associated with allergic sensitization and clinical food allergy in the first year of life.
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IgE-mediated food allergy is one of the earliest manifestationsof allergic disease and is a major public health concern,affecting ~10% of infants and 5% of school-aged children1–3.
However, not all individuals who produce allergen-specific IgE
(sIgE) will react upon consumption of the offending allergen and
can eat the food without adverse consequences, a unique clinical
phenotype known as sensitized tolerance4. At present, the extent
of immune system dysfunction in food allergy and the factors that
govern the transition from sensitization to clinical allergy are
largely understudied, particularly in the first year of life when
food allergy develops and when allergenic foods are first intro-
duced into the diet. In fact, elucidating the cellular mechanisms
that account for the differences between innate tolerance, food
sensitization, and food allergy was identified as a top research
priority by the National Academies of Sciences, Engineering, and
Medicine International Expert Panel on Food Allergy in 20175.
Unlike other food allergies, such as egg allergy that naturally
resolves in up to 90% of children by the age of 6 years, peanut
allergic usually persists and is often lifelong6. Furthermore, children
with peanut and treenut allergies are threefold more likely to have a
reaction consistent with anaphylaxis compared with those with
other food allergies2,7. Currently, peanut avoidance remains the
only management strategy; however accidental ingestion is com-
mon and can lead to life-threatening reactions. Understanding why
some infants with peanut sIgE go on to develop peanut allergic,
whereas others do not, is crucial for accurate diagnosis and early
intervention. We have previously shown that food allergy in infancy
is associated with marked differential immune cell profiles and
cytokine production from both the innate and adaptive immune
systems8–11. However, to date, the complete immune profile and
immune system interactions in infants with food sensitization and
food allergy remains to be investigated.
In the present study, we use high-dimensional mass cytometry
to conduct a comprehensive phenotypic and functional investi-
gation of immune parameters in a group of well-characterized 1-
year-old infants with clinical peanut allergic (as defined by
positive food challenge), infants with peanut-sensitized tolerance
(as defined by negative food challenge but the presence of peanut
sIgE), and non-sensitized non-allergic healthy control infants
following in-vitro antigen-specific (peanut) and nonspecific
(Phorbal myristate acetate (PMA)/ionomycin) stimulation. A
combination of high-dimensional, unsupervised computational
analyses and manual gating is used to comprehensively explore
the immune signatures associated with clinical allergy and tol-
erance to peanut in the first year of life.
Results
Subjects and study design. A subset of thirty-six 1-year-old
infants from the population-based HealthNuts cohort (n= 5276)12
were selected for this study (comprising n= 12 each of challenge-
confirmed peanut-allergic (PA) infants, peanut-sensitized tolerant
(PST) infants, and non-sensitized, non-food-allergic (NA) infants)
(Fig. 1). Oral food challenges (OFCs) were performed in all subjects
according to standardized protocols, as detailed in the Methods
section, to confirm peanut allergic status. PA infants were defined
as having a skin prick test (SPT) wheal diameter ≥2mm or an sIgE
level of ≥0.35 kUA/L to peanut, and an unequivocal objective
allergic reaction during peanut OFC at age 1 year. PST infants had
a positive SPT ≥2mm and sIgE level of ≥0.35 kUA/L to peanut and
a negative peanut OFC at age 1 year. Healthy control infants (the
NA group) were non-sensitized and non-allergic, with a negative
SPT to peanut, egg, sesame, and cow’s milk together with a
negative peanut OFC outcome at age 1 year. Table 1 describes the
demographics and clinical characteristics of the three groups. The
PST and PA infants showed greater peanut sIgE and SPT values
than any of the NA infants. Although the peanut sIgE levels were
comparable between the PST and PA infants, the PST participants
had on average smaller SPT values than the PA infants (Supple-
mentary Fig. 1).
Mass cytometry as a tool for immune profiling in infants. We
first determined the cellular phenotype and frequencies obtained
by mass cytometry in unstimulated cells within the NA healthy
infants (n= 12). Table 2 and Fig. 2a show the results of manual
gating analysis for the major cell populations: CD4 T cells, CD8
T cells, B cells, narural killer (NK) cells, monocytes, and dendritic
cells (DCs) (as percentage of live cells). The subsequent analysis
of all 36 infants, stratified by clinical outcome, in this study is
shown in Fig. 2b. A summary of sub-typing of the major popu-
lations is reported in Table 2 and in Fig. 2c.
Nonspecific stimulation of peripheral blood mononuclear cells
(PBMCs) with PMA/ionomycin and assessment of intracellular
cytokine production were employed to assess the capacity of cells
to respond to activation. Each of NK, CD4 T, CD8 T, B cells,
monocytes, and DCs from NA individuals responded to
stimulation. Interestingly, NK cells produced the most cytokines
of any cell population, with 53.65% (range: 26.2–77.8%) of NK
cells producing interferon-γ (IFNγ) and 31.9% (9.24-47.6%)
producing tumor necrosis factor-α (TNFα) (Fig. 2d). CD4 and
CD8 T cells responded similarly, producing a range of IFNγ,
interleukin-2 (IL-2), and TNFα. B cells, monocytes, and DCs
produced only TNFα following stimulation (Fig. 2d).
Immune profiling by unsupervised analysis. Clustering analysis
with FlowSOM13 using 18 lineage markers revealed 16 cell clus-
ters (Fig. 3a). Based on the expression of lineage markers, the
clusters were classified into the following 11 cell types with the
following frequencies (% live cells): naive CD4 T cells (CD3+
CD4+ CD45RA+ CCR7+ (37.79%)), effector memory CD4
T cells (CD3+ CD4+ CD45RA− CCR7− HLADR−(5.35%)),
HLADR+ effector memory CD4 T cells (CD3+ CD4+
CD45RA−CCR7− HLADR+ (2.36%)), central memory CD4
T cells (CD3+ CD4+ CD45RA− CCR7+ (1.30%)), regulatory
T cells (Tregs) (CD3+ CD4+ CD25+ CD127− (2.26%)), naive
CD8 T cells (CD3+ CD8+ CD45RA+ CCR7+ (10.81%)), effector
memory CD8 T cells (CD3+ CD8+ CD45RA− CCR7− (1.28%)),
central memory CD8 T cells (CD3+ CD8+ CD45RA− CCR7+
(1.03%)), B cells (cluster 1, CD3− CD19+ CD20+ HLADR+
(7.23%)), B cells (cluster 2, CD3− CD19++ CD20+ HLADR++
(12.19%)), NK cells (CD3− CD19− CD14− CD56+ (1.8%)), DCs
(CD3− CD19− CD56− CD14− HLADR+ (1.88%)), and mono-
cytes (CD3− CD19− CD56− CD14+ HLADR+ CD11c+
(1.62%)). Three clusters were unable to be confidently classified,
including undefined CD3+ T cells (two clusters combined; 5.87%,
both negative for CD4 and CD8) and a cluster that was negative
for all markers (4.3%). These three clusters have been removed
from statistical analysis comparing the three study groups. The
frequency of each of the clusters identified by unsupervised
analysis from the 36 infants in this study is shown in Fig. 3b.
Importantly, the frequencies of the major cell types identified
by unsupervised analysis were comparable to those obtained by
manual gating (Supplementary Fig. 2A). Specifically, median
frequencies (% live cells) across the 36 infants of each major
population identified by manual gating vs unsupervised cluster-
ing, respectively, were: CD4 T cells (44.53 vs. 46.86), CD8 T cells
(12.33 vs. 13.66), B cells (20.07 vs. 19.9), NK cells (1.99 vs. 1.37),
monocytes (1.42 vs. 1.36), and DCs (0.89 vs. 0.92). Frequencies of
the major cell populations as determined by unsupervised
clustering for individual infants are presented in Supplementary
Fig. 2B. To further verify our clustering results and to visualize
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this high-dimensional data, we performed a Uniform Manifold
Approximation and Projection (UMAP) analysis as shown in
Fig. 3c. The cells were color highlighted by their respective
FlowSOM cluster. CD4 T-cell subpopulations, CD8 T-cell
subpopulations, B-cell populations, and the myeloid populations
cluster together within two-dimensional space, corresponding
well to the automatically defined clusters.
Immune signatures that discriminate allergy from tolerance.
We next compared resting cell populations between PA infants,
PST infants, and NA controls. Results of our unsupervised clus-
tering, followed by mixed-effects model analysis, revealed significant
differences between the three groups in the abundance of two
clusters, corresponding to the naive CD4 T-cell cluster (p= 0.007,
χ2= 9.9, false discovery rate (FDR)-adjusted p= 0.045, χ2-test,
Fig. 4a) and the CD19++HLADR++ B cell (B-cell cluster 2) (p=
0.005, χ2= 10.8, FDR-adjusted p= 0.045, χ2-test, Fig. 4b). Pairwise
post-hoc analyses revealed that PA infants show increases in the
frequency of these B cells relative to PST and NA infants (p= 0.001,
χ2= 10.2 and p= 0.01, χ2= 6.6, respectively, χ2-test) (Fig. 4b). PST
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Fig. 1 Experimental workflow for mass cytometry analysis of PBMCs from 1-year-old infants. Cryopreserved PBMCs from n= 12 peanut-allergic (PA),
n= 12 peanut-sensitized tolerant (PST), and n= 12 non-allergic (NA) healthy 1-year-old infants were thawed and underwent a 24 h stimulation with media
(control), pure peanut protein (specific stimulation), or PMA/ionomycin (nonspecific stimulation). Samples were barcoded and stained with a panel of
antibodies against 24 surface markers and 8 intracellular markers, and analyzed with a Helios Mass Cytometer. For data analysis, unsupervised
computational analyses (clustering and visualization) and manual gating analyses were performed in parallel, along with statistical analyses to identify
immune signatures significantly different between the clinical groups.
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infants, however, show reduced frequency of naive CD4 T cells
relative to both PA infants (p= 0.043, χ2= 4.1, χ2-test) and NA
controls (p= 0.006, χ2= 7.6, χ2-test) (Fig. 4a). The results of this
unsupervised analysis were confirmed by manual gating (Supple-
mentary Fig. 3A, B). Rare populations of interest not detected by
unsupervised clustering were also interrogated by manual gating.
This revealed that the plasmacytoid DC population (CD123+
CD11c− DCs) were significantly different in frequency between the
three groups (p= 0.024, χ2= 7.5, χ2-test; Fig. 4c). PST infants
showed a significant increase in this population relative to NA
controls (p= 0.005, χ2= 7.8, χ2-test).
To determine any functional differences between the clinical
phenotypes, we compared cellular activation (as measured by
intracellular cytokine production) after nonspecific stimulation
with PMA/ionomycin. A significant difference in the frequency of
TNFα+ cells across all live cells was observed between the three
groups (p= 0.015, χ2= 8.4, χ2-test; Fig. 4d), with PBMCs from
PA infants showing more TNFα+ cells relative to NA controls
(p= 0.0079, χ2= 7.1, χ2-test; Fig. 4d). The median intensity of
TNFα was also different across all live cells (p= 0.0065, χ2= 10.1,
χ2-test), with PA infants expressing higher levels of TNFα per
cells than the non-allergic controls (p= 0.017, χ2= 5.7, χ2-test;
Supplementary Fig. 3C). Following stimulation, NK cells
produced the greatest amount of TNFα (median 25.25% of NK
cells across the three groups) (Supplementary Table 2). Infants
with PA showed the greatest median production of TNFα for B
Table 1 Demographics and clinical characteristics of study cohort.
NA PST PA p*
Total number 12 12 12
Sex: male, n (%) 5 (42%) 7 (58%) 8 (67%) 0.59
Both parents born in Australia, n (%) 11 (92%) 8 (67%) 5 (42%) 0.04
Family history of allergya, n (%) 9 (75%) 9 (75%) 8 (67%) 1
Eczema at age 1 yearb, n (%) 4 (33%) 6 (50%) 5 (42%) 0.91
Peanut SPT (mm), median (IQR) 0 (0) 3.25 (1.38) 9.0 (2.0) 0.0001**
Peanut sIgE (kUA/L)c, median (IQR) 0.005 (0.015) [3 ND] 1.14 (1.24) 4.24 (10.54) [3 ND] 0.11**
Egg allergic, (%) 0 (0%) 9 (75%) 10 (83%) <0.0001 (1**)
Sesame allergic 0 (0%) 0 (0%) 0 (0%) 1
Sensitized to cow’s milkd 0 (0%) 1 (8%) 2 (17%) 0.45
Sensitized to house dust mited 0 (0%) 1 (8%) 2 (17%) 0.76
IQR interquartile range, ND data not available.
*p-values by Fisher’s exact test between the three groups.
**p-values by Fisher’s exact test or Wilcoxon’s rank-sum test for the comparison between PST and PA.
aAsthma, allergic rhinitis, eczema, or food allergy.
bDoctor diagnosed eczema requiring topical steroid treatment or eczema observed by a trained nurse.
cValues at the lower detection limit of 0.01 kUA/L were set to 0.005.
dSkin prick test≥2mm.
Table 2 Summary of cell frequencies (% of parent) by manual gating within the healthy infants (group NA, n= 12).
Parent population Cell population Minimum 1st Quartile Median Mean 3rd Quartile Maximum
Live cells CD4 T cells 39.8 41.83 45.59 47.7 50.94 64.24
CD8 T cells 3.23 11.34 13.42 12.66 14.83 19.85
B cells 10.24 13.97 17.09 18.28 23.47 26.08
NK cells 0.37 1.43 2.0 1.9 2.42 2.95
Monocytes 0.36 1.33 1.42 1.59 1.77 3.06
DCs 0.42 0.51 0.81 1.75 1.16 9.74
CD4 T cells Naive CD4 T cells 42.8 59.25 63.9 62.93 67.25 77.8
Central memory CD4 T cells 13.2 17.65 20.2 20.93 22.62 34.5
Effector memory CD4 T cells 4.11 5.66 7.28 8.77 10.62 19.4
Effector CD4 T cells 3.29 4.62 5.89 7.37 10.22 17.6
Regulatory T cells 2.74 3.9 4.62 4.43 5.22 5.45
CD8 T cells Naive CD8 T cells 58.1 63.85 68.2 70.8 79.08 84.5
Central memory CD8 T cells 3.99 5.31 6.39 6.64 7.5 11.9
Effector memory CD8 T cells 3.66 6.54 12.45 10.99 13.85 19.3
Effector CD8 T cells 5.21 6.75 12.15 11.56 13.78 20.7
B cells Naive B cell 92.0 95.57 96.15 95.97 96.82 98.8
Memory B cells 1.21 3.15 3.84 4.03 4.42 8.05
NK cells CD56+CD16+ NK 20.2 48.17 55.7 53.19 64.75 67.2
CD56+CD16- NK 20.3 22.77 25.3 31.82 34.45 76.7
CD56brightCD16+ NK 0.78 2.21 2.84 3.25 3.34 8.97
CD56brightCD16− NK 2.34 7.3 11.65 11.76 13.65 27.7
Monocytes CD14+CD16+ monocytes 4.83 46.77 53.0 49.73 56.73 70.6
CD14+CD16− monocytes 29.4 43.27 47.0 50.27 53.23 95.2
DCs mDC % HLADR+ 13.0 24.55 30.0 36.69 44.82 80.7
pDC % HLADR+ 0.65 1.36 2.32 2.44 3.24 5.24
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cells, CD4 T cells, monocytes, pDCs, and mDCs, although only
the pDC subset reached significance (Supplementary Table 2).
Unsupervised analysis of the PMA/ionomycin-stimulated
samples revealed ten clusters of known cell populations
(Supplementary Fig. 4A). We observed a significant difference
in IL-2 levels within the naive CD4 T-cell cluster (p= 0.007, χ2=
9.8, FDR-adjusted p= 0.077, χ2-test; Fig. 4e). PST infants showed
higher IL-2 relative to both the PA and NA controls (p= 0.046,
χ2= 4.0 and p= 0.005, χ2= 7.9, respectively, χ2-test). This was
confirmed by manual gating, which revealed greater median IL-2
expression in naive CD4 T cells from both PA and PST infants (p
= 0.032, χ2= 4.6 and p= 0.044, χ2= 4.1, respectively, χ2-test;
Supplementary Fig. 4B). The frequency of IL-2+ cells in naive
CD4 T cells was also higher in PA and PST infants relative to NA
controls (p= 0.015, χ2= 5.9 and p= 0.008, χ2= 7.1, respectively,
χ2-test; Supplementary Fig. 4C).
IFNγ levels were significantly different between the three
groups in the effector memory CD4 T-cell cluster expressing
increased levels of HLA-DR (p= 0.009, χ2= 9.4, FDR-adjusted p
= 0.077, χ2-test; Fig. 4f). Pairwise post-hoc analyses showed
significantly lower levels in PA and PST infants compared with
NA controls (p= 0.033, χ2= 4.5 and p= 0.008, χ2= 7.1,
respectively, χ2-test). These trends from the unsupervised analysis
were confirmed when comparing the median IFNγ levels in
manually gated effector memory CD4 HLA-DR+ T cells
(Supplementary Fig. 4D). When comparing our findings of the
unsupervised analysis of median expression with the manually
gated percent of IFNγ+ effector memory CD4 HLA-DR+ T cells
between the groups, the trend can be seen but is not reflected as
significant changes (Supplementary Fig. 4E).
Peanut-specific T cells in allergic but not tolerant infants. To
investigate whether the transition from sensitization to allergy
involves changes in the frequency and phenotype of peanut-
specific CD4 T cells, we quantified CD40L+CD69+ antigen-
activated CD4 T cells14 by manual gating following stimulation
with pure peanut protein solution (Fig. 5a). This revealed that
PA infants show an increased percentage of peanut-specific
CD4 T cells (median: 0.063%, (range: 0.013–0.12%)) relative
to both PST (0.026% (0.0068–0.091%)) and NA (0.038%
(0.0023–0.073%)) infants following in-vitro stimulation with
peanut (p= 0.019, F= 6.5 and p= 0.028, F= 5.5, respectively, F-
test; Fig. 5b). Stimulation with peanut induced a median 1.79-fold
increase (range: 1.17–2.18) in peanut-specific CD4 T cells in PA
infants, which was significantly greater than the median 1.33-fold
increase (0.39–2, p= 0.012, F= 7.7, F-test) in PST and the 1.22-
fold increase (0.59–2.52, p= 0.022, F= 6.1, F-test) in NA infants
(Fig. 5c). To next determine the phenotype of these peanut-
specific CD4 T cells, markers of activation and memory
were used to distinguish effector (CD45RA+CCR7−), effector
memory (CD45RA−CCR7−), and central memory phenotypes
(CD45RA−CCR7+). This revealed that infants with peanut
allergic show more peanut-specific CD4 T cells within the
CD45RA− memory phenotypes that are not observed in PST and
non-allergic infants (Supplementary Fig. 5A–D).
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Fig. 2 Immune cell profiling of unstimulated PBMCs from 1-year-old infants by manual gating. a The six major immune cell populations identified in
unstimulated PBMC expressed as percentage of live cells in n= 12 healthy 1-year-old infants. b Stacked bar graph representing the major immune cell
populations in each individual, stratified by clinical outcome for non-allergic (NA) (n= 12), peanut-sensitized tolerant (PST) (n= 12), and peanut-allergic
(PA) (n= 12) infants. c Each major immune cell population was subtyped into further populations in unstimulated PBMC from n= 12 healthy infants.
d Percentage of CD4 T cells, CD8 T cells, B cells, NK cells, monocytes, and dendritic cells (DCs) producing IFNγ, TNFα, or IL-2 following 24 h stimulation of
PBMC with PMA/ionomycin in n= 12 healthy infants. In the boxplots, the medians are shown. The “hinges” represent the first and third quartile. The
whiskers are the smallest and largest values after exclusion of outliers (greater than the 75th percentile plus 1.5 times the IQR or less than 25th percentile
minus 1.5 times the IQR). Source data are provided as a Source Data file.
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Discussion
This study performed high-dimensional mass cytometry-based
single-cell profiling of resting and stimulated PBMCs to identify
the circulating immune cell signatures associated with peanut
sensitization with tolerance (PST) vs. clinical peanut allergic (PA).
Unsupervised clustering and mixed-effects model analysis of cell
frequency revealed that PA is associated with increased frequency
of CD19++HLADR++ B cells compared with PST infants. In
comparison, PST was associated with reduced frequency of
CD45RA+CCR7+ naive CD4 T cells and increased frequency of
plasmacytoid DCs compared with healthy infants. Functional
analysis of intracellular cytokine production following PMA/
ionomycin stimulation revealed increased global expression of
TNFα across all single cells in PA infants and increased IL-2
expression in the naive CD4 T-cell cluster in PST infants. In
addition, investigation of the peanut-specific T-cell response by
expression of CD40L and CD69 on CD4 T cells following peanut
stimulation revealed that PA, but not PST, is characterized by
increases in peanut-activated CD4 T cells that display a memory
phenotype.
These findings highlight the utility and power of high-
dimensional mass cytometry, in combination with unsupervised
and manual analysis techniques, to interrogate the cellular
interactions that could explain the development of allergic sen-
sitization with tolerance vs. clinical food allergy in the first year of
life. Importantly, analysis by mass cytometry revealed cell fre-
quencies comparable to that obtained previously with flow
cytometry in the same age-matched HealthNuts cohort8–10. In
the current study, the key features associated with PA
were increased frequency of a unique subset of B cells
(CD19++HLADR++) and overproduction of TNFα following a
nonspecific stimulation. We and others have previously shown an
increased production of inflammatory cytokines, including TNFα,
from myeloid cells in food-allergic patients9,15. In the current
study, by far the greatest producers of TNFα following stimula-
tion were NK cells, followed by CD4 T cells and monocytes, with
a small proportion of DCs, CD8 T cells, and B cells also con-
tributing to this global inflammatory response. The PA group
showed the greatest mean production of TNFα across NK cell,
CD4 T cell, monocyte, DC, and B-cell populations. Together,
these findings confirm that highly complex cellular inflammatory
responses play an important role in the development of food
allergy. Interestingly, a recent study investigating the phenotype
of peripheral B cells in systemic lupus erythematosus (SLE)
identified a similar increase in CD19++HLADR++ cells in SLE
patients relative to healthy controls16. The authors showed this
NA PST PA
P0
3
P1
0
P0
7
P1
1
P0
2
P0
6
P0
4
P0
8
P1
2
P0
1
P0
5
P0
9
P2
0
P2
2
P1
9
P2
1
P1
8
P1
6
P2
4
P1
4
P2
3
P1
7
P1
5
P1
3
P3
6
P2
8
P3
1
P3
2
P2
9
P3
3
P2
5
P3
5
P2
6
P3
0
P3
4
P2
7
0%
25%
50%
75%
100%
Participants
%
 li
ve
 c
el
ls
FlowSOM cluster
Below cluster size cutoff
Undfined
CD3+ (CD27+ CXCR3+ CD127+)
CD3+
NK
Monocyte
DC
B cell (cluster 1)
B cell (cluster 2)
Treg
Effector memory CD8
Central memory CD8
Naive CD8
Effector memory CD4
Effector memory CD4 (HLA-DR+)
Central memory CD4
Naive CD4
B cells (cluster 1)
Naive CD4+ T cells
Regulatory T cells
Effector memory 
CD4+ T cells
Central memory 
CD4+ T cells
Monocytes
Dendritic 
cells
Natural killer
cellsUndefined
Naive 
CD8+
T cells
Central memory 
CD8+ T cells
Effector memory 
CD8+ T cellsCD3+ 
cells
CD3+ (CD27+
CXCR3+ CD127+)
B cells (cluster 2)
Effector memory 
CD4+ T cells 
(HLA-DR+)
DC
Monocyte
B cell
B cell 2
CD3+ 2
Effector memory CD4
Effector memory CD4 (HLA−DR+)
undfined
NK
Central memory CD8
Naive CD8
Effector memory CD8
CD3+
Central memory CD4
Naive CD4
Treg
0 10 20 30
% live cells
Median expression [arcsinh]
0 1 2 3 4 5 6
10
10
5
5
0
0
–5
–5
UM
AP
2
UMAP1
–10
–10
40
Treg
Naive CD4
Central memory CD4
CD3+ (CD27+ CXCR3+ CD127+)
Effector memory CD8
Naive CD8
Central memory CD8
NK
Undefined
Effector memory CD4
CD3+
B cell (cluster 1)
B cell (cluster 2)
Monocyte
DC
CD27
CD3
H
LA.D
R
CD11c
CD38
CD16
CD56
CD45RA
CD19
CD20
CD25
CD123
CD14
CXCR3
CD127
CD8
CD4
CCR7
Effector memory CD4 (HLA-DR+)
a
b
c
Fig. 3 Unsupervised analysis using FlowSOM reveals distinct immune cell clusters in PBMC from 1-year-old infants. a Clustering analysis with
FlowSOM revealed 16 cell clusters, shown here as a heatmap of the median expression of 18 lineage markers along with a bar graph representing each
cluster as percentage of live cells and the cell phenotype that each cluster was assigned based on lineage marker expression pattern. b Stacked bar graph
representing all clusters identified in each individual, stratified by clinical outcome for non-allergic (NA) (n= 12), peanut-sensitized tolerant (PST) (n= 12),
and peanut-allergic (PA) (n= 12) infants. Clusters with <1% of the analyzed cells were excluded from all other analyses and are represented here as “below
cluster size cutoff”. c Uniform Manifold Approximation and Projection (UMAP) representation of 100,008 randomly selected cells (2778 per file) with
clusters from the FlowSOM analysis overlaid. The same color is used for each cluster/cell type across all plots. Source data are provided as a Source
Data file.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14919-4
6 NATURE COMMUNICATIONS |         (2020) 11:1091 | https://doi.org/10.1038/s41467-020-14919-4 | www.nature.com/naturecommunications
subset of cells produced more immunoglobulin relative to the
CD19+ population and showed an upregulation of genes involved
in B-cell activation and differentiation. Whether this activated
B-cell subset is responsible for the increased IgE observed in PA
needs to be further investigated in in-vitro studies.
Both a reduced frequency of naive CD4 T cells and increased
expression of IL-2 in this cell subset following stimulation were
signatures uniquely associated with PST. IL-2 has recently been
described to be critical in the maintenance of immune tolerance
(comprehensively reviewed in ref. 17). Clinical research has
shown that IL-2 therapy is effective in promoting tolerance in
autoimmune and inflammatory conditions, primarily by enhan-
cing the development and maintenance of regulatory T cells18. In
this study, we additionally report that an increase in plasmacytoid
DCs, also known for their tolerogenic immune properties against
innocuous antigens19,20, to be unique to infants with PST. These
cells may play a central role in averting clinical allergy in the
presence of allergen-sIgE.
Few studies have investigated the immune response of infants
who are sensitized but clinically tolerant to peanut. Previous
work investigating the plasma cytokine profiles of 119 infants
with sensitized tolerance or clinical allergy to food (peanut or
egg) showed that IL-10 and IL-6 were significantly higher in
those sensitized compared with those who were allergic, and that
IL-4 and IL-13 were higher in sensitized relative to non-
sensitized infants21. Basophil-activation tests in PA children
showed upregulation of basophil-activation markers CD63 and
CD203c following peanut stimulation; however, there was no
response to peanut in those who were peanut-sensitized but
tolerant22. We also examined the peanut-specific response in
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this cohort by analyzing upregulation of CD40L and CD69 as
markers of antigen-stimulated CD4 T cells following peanut
stimulation, as previously described14,23,24. We showed an
increase in peanut-specific effector CD4 T cells following peanut
stimulation in PA infants; however, no response to peanut in
those who were PST and NA. Previous work investigating
peanut-specific T-cell responses have been hindered by technical
difficulties in identifying these rare cells in the circulation.
Tetramer-based technology provides specific and sensitive
measures of allergen specificity; however, they require T-cell
expansion cultures and knowledge of HLA (human leukocyte
antigen) status25–27. Evaluating peanut specificity via the CD154
and CD69 upregulation assay reported in our study, both
markers of T-cell receptor activation, allows improved detection
of these rare cells after a short-term culture with endotoxin-free
pure peanut solution.
We acknowledge this study has several limitations. Although
comprehensive for the well-characterized lymphoid and myeloid
markers, a limitation of our antibody panel is that it does not
include surface markers for innate-like and unconventional
T-cell populations, or subsets of immunoglobulin switched/non-
switched B cells, which may be relevant for the the development
of an allergic immune response28,29. It should also be considered
when interpreting our findings that, as blood collection was
performed following clinical testing, a positive peanut OFC
could influence some of the immune parameters investigated in
this study. As such, the results presented represent a snapshot of
the immune response following in vivo allergen exposure.
However, we have previously reported no differences in cellular
activation or plasma cytokine production in food-allergic infants
who had a blood sample taken on a non-OFC day vs. an active
OFC day9,21. It will be interesting to determine whether these
signatures can be identified prior to allergen challenge and
we acknowledge these are important areas for future investiga-
tion into the development of peanut sensitization and allergy in
the first year of life.
This study uses mass cytometry to provide a detailed char-
acterization of the circulating immune cell profiles that are
associated with challenge-proven food allergy and asymptomatic
food sensitization in the first year of life. The results provide a
framework for future investigation into the roles of these unique
immune signatures in predicting the transition from sensitization
to allergy.
Methods
Oral food challenges and serum sIgE. OFC to peanut were performed in all
subjects according to standardized protocols30. Briefly, food challenge involved
gradually increasing doses on day 1 in the hospital and continued ingestion of the
maximum day 1 dose (1 teaspoon of peanut butter) on days 2 through 7.
HealthNuts-standardized cessation criteria for a positive OFC result were any of
the following occurring within 2 h of ingestion: three or more concurrent non-
contact urticaria persisting for at least 5 min, perioral or periorbital angioedema,
vomiting, and evidence of circulatory or respiratory compromise30. Serum sIgE was
measured using the ImmunoCAP System FEIA (Phadia AB). Values at the lower
detection limit of 0.01 kUA/L were set to 0.005 kUA/L.
Cell culture and preparation of cells for mass cytometry. Blood was collected at
clinic appointments 2 h following peanut OFC and PBMCs were isolated from
whole blood by density gradient and cryopreserved as detailed previously11. Briefly,
up to 7 mL of blood was collected from each infant into a sodium heparin tube
(Sarstedt) and plasma removed by centrifugation within 1 h of collection at 700 × g
for 10 min at room temperature. A 1:1 ratio of RPMI media was added to cells
before layering onto 5.0 mL of Ficoll-Paque solution and brake-free centrifugation
at 400 × g for 30 minutes. Mononuclear cells at the interface of media and Ficoll-
Paque solution were aspirated and washed twice in RPMI containing 2% heat-
inactivated fetal calf serum (FCS) by centrifugation at 500 × g for 7 min. PBMCs
were cryopreserved in liquid nitrogen at 10 × 106/ml in RPMI with 15% dimethyl
sulfoxide in FCS.
For cell culture, PBMCs were thawed in 10 mL cell culture media (RPMI
supplemented with 10% heat-inactivated FCS and penicillin streptomycin) with
25 U/mL benzonase at 37 °C. PBMCs were centrifuged at 300 × g for 10 min and
washed twice in culture media before viability count using the NucleoCounter NC-
200. Mean viability after thawing was 90.5%. Cells were resuspended at 2 × 106/mL
in cell culture media for overnight rest in a T25 flask at 37 °C, 5% CO2. Following
overnight rest, cells were then resuspended at 3 × 106/200 µL and cultured in U-
bottom 96-well plates with ether (i) media alone, (ii) 200 µg/ml of endotoxin cleaned
pure peanut protein solution (Greer: XPF171D3A2.5: Ara h 1 content: 71.03 µg/mL,
Ara h 2 content: 78.43 µg/mL) for 24 h or (iii) 20 ng/mL PMA/1 µg/mL ionomycin
combined solution for the final 4 h. PMA/ionomycin was chosen as a nonspecific
cell stimulus and as a positive control in our assay to ensure cells were responsive
to stimulation. To inhibit extracellular cytokine transport, Brefeldin-A was added
to all wells after 20 h. Following cell culture, PBMCs were centrifuged at 300 × g for
7 min, resuspended in 200 µl-filtered CyFACS buffer (0.1% bovine serum albumin,
0.1% sodium azide, 2 mM EDTA in PBS) and transferred to V-bottom 96-well
plates for staining.
All of the following cell staining steps prior to barcoding were performed in V-
bottom 96-well plates, with wash steps in 200 µl CyFACS buffer and centrifugation
at 300 × g for 7 min. PBMCs were resuspended in 70 µl of surface antibody cocktail
(Supplementary Table 1) and incubated for 30 min at room temperature. Cells were
then washed three times and resuspended in 100 µl of live/dead 115-DOTA
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maleimide (stock 5 mg/ml, diluted 1:3000) for 15 min at room temperature. Cells
were then washed a further three times prior to transfer into polypropylene
fluorescence-activated cell sorting tubes and barcoding using the Cell-ID 20-Plex
Pd Barcoding Kit (Fluidigm) according to manufacturer’s instructions. PBMCs
were then resuspended in 100 µl of 2% paraformaldehyde (PFA) in CyPBS (filtered
PBS) and incubated overnight at 4 °C. The next day, cells were resuspended in 2 ml
CyFACS buffer and centrifuged at 600 × g for 5 min at 4 °C. Following cell count,
an equal number of cells from each infant were pooled into a single 15 ml tube and
centrifuged at 600 × g for 5 min at 4 °C. For permeabilization, cells were
resuspended in 2 ml of permeabilization buffer (EBioscience) and centrifuged at
600 × g for 5 min at 4 °C. Following a second wash in 2 ml permeabilization buffer,
pooled cells were resuspended in 100 µl of intracellular antibody cocktail
(Supplementary Table 1) and incubated for 30 min at room temperature. Cells were
then washed once in 2 ml of permeabilization buffer, followed by two washes in 2
mL CyFACS buffer. For every sample within the pooled tube, 100 µl of Ir-
Interchelator (1:2000, diluted in 2% PFA in CyPBS) was added and incubated
overnight at 4 °C. On the day of mass cytometry acquisition, cells were washed
twice in CyFACS buffer, followed by one wash in CyPBS and two further washes in
milliQ water. All wash volumes were in 2 ml and centrifugation was at 600 × g for
5 min at 4 °C. Samples were acquired on the mass cytometer (Helios, Fluidigm)
after standard instrument setup procedures.
Mass cytometry data analysis. Following normalization and de-barcoding, FCS
files underwent standard pre-processing to remove debris, doublets and to enrich
for live cells (Supplementary Fig. 6). Live, single cells were analyzed by manual
gating and unsupervised computational methods in parallel.
For manual gating, major immune cell populations were identified based on the
gating strategy outlined in Supplementary Fig. 7 using FlowJo V10.6. Briefly, CD3
and CD19 were first used to determine pan T and B cells, respectively. Within the
B-cell population, naive and memory B cells were identified based on CD27
expression. Within the T-cell population, CD4 and CD8 T cells were identified. For
CD8 T cells, naive, effector, central memory, and effector memory subpopulations
were identified based on CD45RA and CCR7 expression. For CD4 T cells, Tregs
were determined based on CD25+CD127low expression and a “not Treg” gate was
created to then identify CD4 naive, effector, central memory, and effector memory
subpopulations based on CD45RA and CCR7 expression. NK cells were identified
from within the CD3−CD19− population based on CD56 expression.
Subpopulations of NK cells were also determined based on the brightness of CD56
and expression of CD16. Finally, CD3−CD19−CD56− cells were then separated
into monocytes, based on CD14 expression (subpopulations of monocytes also
identified based on CD16 expression) and DCs based on CD14−HLADR+
expression, where DC subsets were determined by CD11c (myeloid) and CD123
(plasmacytoid) expression. CD49b and LAG3 were excluded from manual and
computational analysis due to limited expression across all samples. For cytokine
production following 24 h stimulation with PMA/ionomycin, IL-2, TNFα, and
IFNγ expression were analyzed in all cell populations (Supplementary Fig. 8). IL-
10, IL-4, and IL-17A were excluded from manual and computational analysis due
to limited expression across all samples.
For quantification of antigen-specific CD4 T cells following peanut stimulation,
CD40L+CD69+ cells were identified within the CD4 T-cell population by manual
gating14. For one of the PA infants, due to limited cell number, no peanut
stimulation was performed, reducing the size of that group for this analysis to
n= 11. To analyze the impact of peanut stimulation on the frequency of allergen-
specific cells within CD4 T cells between the three groups, per infant, the fold
change of frequency of these cells after peanut stimulated over the frequency when
unstimulated was calculated. Pairwise linear models with F-test were used to
compare the determined frequencies or fold changes between the three groups.
P < 0.05 was considered significant.
Unsupervised computational analysis was performed separately for
unstimulated and PMA/ionomycin-stimulated samples. In each case, 50,000 cells of
the pre-gated live, single cells were randomly selected and values were arcsinh
(inverse hyperbolic sine) transformed with a cofactor of 531. As introduced
previously as a strategy to analyze mass cytometry data32, we separated the markers
into lineage markers (CD3, CD4, CD8, CCR7, CD45RA, CD25, CD127, CD27,
CXCR3, CD19, CD20, CD38, CD56, CD14, CD16, HLA-DR, CD11c, and CD123)
and functional markers (IFNγ, TNFα, and IL-2). For the nonspecifically stimulated
samples CD127, CXCR3 and CD27 were excluded due to batch effects. To adjust
for between-sample and batch variation, a subset of the lineage markers (all but
CD45RA and CD38 for unstimulated and all for the PMA/ionomycin-stimulated
samples) were subjected to the landmark alignment procedure33, using the warpSet
R function in the flowStats package (version 3.40.1). The warping functions were
determined using all live, single cells per file and not just the randomly selected
cells. Subsequently, unsupervised clustering was performed on the expression
values of the lineage markers using the FlowSOM algorithm13 (R package
FlowSOM, version 1.14.1), which uses a self-organizing map followed by
hierarchical consensus meta-clustering to detect cell populations. Default
parameters and a predetermined number of 25 clusters were used. Clusters with
<1% of the analyzed cells were excluded.
The median levels of the lineage markers across all cells per cluster were
visualized in a heatmap for the unstimulated and PMA/ionomycin-stimulated
samples (R package pheatmap, version 1.0.1234). The type of cells within a cluster
was based on the levels of expression of specific lineage markers. For the
unstimulated samples, we applied the non-linear dimensionality reduction
technique UMAP to the lineage marker levels of a set of randomly selected 100,008
cells (2778 cells per file) using the R package UMAP (version 0.2.0.0, default
parameters except min_dist= 0.25) for visualization of the high-dimensional
data35. The cells were colored according to their FlowSOM cluster membership.
Clusters for which no known cell type could be identified based on surface marker
expression were included in the heatmap and UMAP but were excluded from the
subsequent analysis.
For the unstimulated samples, the percentage of the randomly selected cells of
each file in each cluster was determined and the values were compared between the
three groups per cluster using a linear mixed-effects model with batch (five
batches) as random effect. P-values were determined by χ2-test (2 degrees of
freedom (DF)) and adjusted for multiple comparisons using the Benjamini and
Hochberg approach to control the FDR36. In this analysis, 13 tests were performed
and FDR-adjusted p < 0.1 were considered significant. For each of the clusters
showing a significant difference between the three groups, a descriptive post-hoc
analysis by a series of additional mixed-effects models and χ2-tests (1 DF) each
comparing two groups were performed.
After clustering using FlowSOM, for the PMA/ionomycin-stimulated samples,
median levels of the functional markers per cluster per file were compared between
the three groups in the mixed-effects models. P-values by χ2-test were FDR-adjusted
and features significantly different between the three groups (FDR-adjusted p < 0.1,
total number of tests: 25) were analyzed in pairwise post-hoc mixed-effects models.
Median levels were plotted after adjustment for batch in linear models.
Manual gating was used to confirm detected significant changes from the
unsupervised analysis as well, to study rare and specific cell types not detected by
the unsupervised analysis. P-values were determined by χ2-tests in mixed-effects
models as in the unsupervised analysis.
In all presented boxplots, the medians are shown. The “hinges” represent the
first and third quartile. The whiskers are the smallest and largest values after
exclusion of outliers (greater than the 75th percentile plus 1.5 times the
interquartile range (IQR), or less than 25th percentile minus 1.5 times the IQR).
When data points for each individual were overlaid on the boxplots, blue dots
represent values determined by manual gating, whereas red dots represent values
derived from the unsupervised analysis using FlowSOM. The statistical analysis was
performed in R (version 3.5.2) and plotting was done using the ggplot2 R package
(version 3.1.0)37. All statistical tests were performed two-sided.
Ethics. Approval to conduct the HealthNuts study was obtained from the Victorian
State Government Office for Children (reference number CDF/07/492), the Vic-
torian State Government Department of Human Services (reference number 10/
07), and the Royal Children’s Hospital Human Research Ethics Committee
(reference number 27047). Informed consent was obtained from parents or
guardians of all participants.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying all figures and supplementary figures are provided as a
Source Data file.
Received: 4 October 2019; Accepted: 11 February 2020;
References
1. Osborne, N. J. et al. Prevalence of challenge-proven IgE-mediated food allergy
using population-based sampling and predetermined challenge criteria in
infants. J. Allergy Clin. Immunol. 127, 668–676.e1–2 (2011).
2. Sasaki, M. et al. Prevalence of clinic−defined food allergy in early adolescence:
the SchoolNuts study. J. Allergy Clin. Immunol. 141, 391–398 e394 (2018).
3. Vermeulen, E. M. et al. Food allergy is an important risk factor for childhood
asthma, irrespective of whether it resolves. J. Allergy Clin. Immunol. Pract. 6,
1336–1341 e1333 (2018).
4. Nicolaou, N. et al. Allergy or tolerance in children sensitized to peanut:
prevalence and differentiation using component-resolved diagnostics. J.
Allergy Clin. Immunol. 125, 191–197.e1–13 (2010).
5. Oria M. P. & Stallings V. A. (eds). Finding a Path to Safety in Food Allergy:
Assessment of the Global Burden, Causes, Prevention, Management, and Public
Policy (National Academies Press, Washington (DC), 2016).
6. Peters, R. et al. The natural history of peanut and egg allergy and predictors of
persistence: The Healthnuts Longitudinal Study, 6-Year-Old Follow-up. J.
Allergy Clin. Immun. 143, Ab421–Ab421 (2019).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14919-4 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:1091 | https://doi.org/10.1038/s41467-020-14919-4 |www.nature.com/naturecommunications 9
7. McWilliam, V. et al. Patterns of tree nut sensitization and allergy in the first 6
years of life in a population-based cohort. J. Allergy Clin. Immunol. 143,
644–650 e645 (2019).
8. Martino, D. et al. Epigenetic dysregulation of naive CD4+ T-cell activation
genes in childhood food allergy. Nat. Commun. 9, 3308 (2018).
9. Neeland, M. R. et al. Early life innate immune signatures of persistent food
allergy. J. Allergy Clin. Immunol. 142, 857–864 e853 (2018).
10. Neeland, M. R. et al. B cell phenotype and function in infants with egg allergy.
Allergy 74, 1022–1025 (2019).
11. Dang, T. D. et al. Food-allergic infants have impaired regulatory T-cell
responses following in vivo allergen exposure. Pediatr. Allergy Immunol. 27,
35–43 (2016).
12. Koplin, J. J. et al. Cohort profile: The HealthNuts Study: population prevalence
and environmental/genetic predictors of food allergy. Int. J. Epidemiol. 44,
1161–1171 (2015).
13. Van Gassen, S. et al. FlowSOM: Using self-organizing maps for visualization
and interpretation of cytometry data. Cytom. A 87, 636–645 (2015).
14. Lin, D. & Maecker, H. T. Mass cytometry assays for antigen-specific T cells
using CyTOF. Methods Mol. Biol. 1678, 37–47 (2018).
15. Zhang, Y. et al. Cord blood monocyte-derived inflammatory cytokines
suppress IL-2 and induce nonclassic “T(H)2-type” immunity associated with
development of food allergy. Sci. Transl. Med. 8, 321ra328 (2016).
16. Liu, Z. et al. Peripheral CD19(hi) B cells exhibit activated phenotype and
functionality in promoting IgG and IgM production in human autoimmune
diseases. Sci. Rep. 7, 13921 (2017).
17. Perol, L. & Piaggio, E. New molecular and cellular mechanisms of tolerance:
tolerogenic actions of IL-2. Methods Mol. Biol. 1371, 11–28 (2016).
18. Zhao, Z. et al. Fine tuning subsets of CD4(+) T cells by low-dosage of IL-2
and a new therapeutic strategy for autoimmune diseases. Int.
Immunopharmacol. 56, 269–276 (2018).
19. Gehrie, E., Van der Touw, W., Bromberg, J. S. & Ochando, J. C. Plasmacytoid
dendritic cells in tolerance. Methods Mol. Biol. 677, 127–147 (2011).
20. Kohli, K., Janssen, A. & Forster, R. Plasmacytoid dendritic cells induce
tolerance predominantly by cargoing antigen to lymph nodes. Eur. J.
Immunol. 46, 2659–2668 (2016).
21. Dang, T. D. et al. Characterization of plasma cytokines in an infant population
cohort of challenge-proven food allergy. Allergy 68, 1233–1240 (2013).
22. Santos, A. F. et al. Basophil activation test discriminates between allergy and
tolerance in peanut-sensitized children. J. Allergy Clin. Immunol. 134,
645–652 (2014).
23. Weissler, K. A. et al. Identification and analysis of peanut-specific effector T
and regulatory T cells in children allergic and tolerant to peanut. J. Allergy
Clin. Immunol. 141, 1699–1710 e1697 (2018).
24. Renand, A. et al. Heterogeneity of Ara h component-specific CD4 T cell
responses in peanut-allergic subjects. Front. Immunol. 9, 1408 (2018).
25. Birrueta, G. et al. Peanut-specific T cell responses in patients with different
clinical reactivity. PLoS ONE 13, e0204620 (2018).
26. Van Hemelen, D. et al. HLA class II peptide tetramers vs allergen-induced
proliferation for identification of allergen-specific CD4 T cells. Allergy 70,
49–58 (2015).
27. DeLong, J. H. et al. Ara h 1-reactive T cells in individuals with peanut allergy.
J. Allergy Clin. Immunol. 127, 1211–1218 e1213 (2011).
28. Lezmi, G. & Leite-de-Moraes, M. Invariant natural killer T and mucosal-
associated invariant T cells in asthmatic patients. Front. Immunol. 9, 1766
(2018).
29. Saunders, S. P., Ma, E. G. M., Aranda, C. J. & Curotto de Lafaille, M. A. Non-
classical B cell memory of allergic IgE responses. Front. Immunol. 10, 715
(2019).
30. Koplin, J. J. et al. Predetermined challenge eligibility and cessation criteria for
oral food challenges in the HealthNuts population-based study of infants. J.
Allergy Clin. Immunol. 129, 1145–1147 (2012).
31. Bendall, S. C. et al. Single-cell mass cytometry of differential immune and drug
responses across a human hematopoietic continuum. Science 332, 687–696
(2011).
32. Bruggner, R. V., Bodenmiller, B., Dill, D. L., Tibshirani, R. J. & Nolan, G. P.
Automated identification of stratifying signatures in cellular subpopulations.
Proc. Natl Acad. Sci. USA 111, E2770–E2777 (2014).
33. Hahne, F. et al. Per-channel basis normalization methods for flow cytometry
data. Cytom. A 77, 121–131 (2010).
34. Kolde, R. pheatmap: Pretty Heatmaps. 2019.
35. Konopka, T. umap: Uniform Manifold Approximation and Projection. 2018.
36. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate - a practical
and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289–300
(1995).
37. Wickham, H. ggplot2: Elegant Graphics for Data Analysis. 2016.
Acknowledgements
We thank the children and parents who participated in the HealthNuts study. We also
thank current and past staff for recruiting and maintaining the cohort, and processing
the data and biospecimens. We thank Matthew Kirkey for assistance with CyTOF
experiments. This work was supported by funding from the NIH (5R01AI140134,
2U19AI104209, and 5U01AI140498), EAT (End Allergies Together), FARE (Food
Allergy Research & Education), the Sean N. Parker Center for Allergy and Asthma
Research at Stanford University, and the Kim and Ping Li endowment. The HealthNuts
study is supported by funding from the National Health and Medical Research Council
of Australia (NHMRC), the Ilhan Food Allergy Foundation, AnaplyaxiStop, The Charles
and Sylvia Viertel Medical Research Foundation, and the Victorian Government’s
Operational Infrastructure Support Program. M.R.N. is supported by a Melbourne
Children’s Lifecourse Postdoctoral Fellowship.
Author contributions
M.R.N. designed and performed the experiments, analyzed the data, and wrote the
manuscript. S.A. analyzed the data and wrote the manuscript. M.M., D.D., and S.L. con-
tributed to experimental design and assisted with experiments. T.D. collected and pro-
cessed the biospecimens. K.P., M.T., R.P., R.S., and J.K. are HealthNuts investigators and
contributed to study conceptualization. K.C.N. supervised the work, provided funding, and
edited the manuscript. All authors edited and approved the final manuscript.
Competing interests
K.C.N. reports grants and other from NIAID other from Novartis, personal fees and
other from Regeneron, grants and other from FARE, grants from EAT, other from
Sanofi, other from Astellas, other from Nestle, other from BeforeBrands, other from
Alladapt, other from ForTra, other from Genentech, other from AImmune Therapeutics,
other from DBV Technologies, personal fees from Astrazeneca, personal fees from
ImmuneWorks, personal fees from Cour Pharmaceuticals, grants from Allergenis, grants
from Ukko Pharma, other from AnaptysBio, other from Adare Pharmaceuticals, other
from Stallergenes-Greer, other from NHLBI, other from NIEHS, other from EPA, other
from WAO Center of Excellence, other from Iggenix, other from Probio, other from
Vedanta, other from Centecor, other from Seed, from Immune Tolerance Network, from
NIH, outside the submitted work. In addition, K.C.N. has a patent Inhibition of Allergic
Reaction to Peanut Allergen using an IL-33 Inhibitor pending, a patent Special Oral
Formula for Decreasing Food Allergy Risk and Treatment for Food Allergy pending, a
patent Basophil Activation Based Diagnostic Allergy Test pending, a patent Granulocyte-
based methods for detecting and monitoring immune system disorders pending, a patent
Methods and Assays for Detecting and Quantifying Pure Subpopulations of White Blood
Cells in Immune System Disorders pending, a patent Mixed Allergen Compositions and
Methods for Using the Same pending, and a patent Microfluidic Device and Diagnostic
Methods for Allergy Testing Based on Detection of Basophil Activation pending.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-14919-4.
Correspondence and requests for materials should be addressed to M.R.N. or K.C.N.
Peer review information Nature Communications thanks Brice Gaudilliere, Erika
Jensen-Jarolim, and Hugh Sampson for their contributions to the peer review of this
work. Peer review reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons licence, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons licence and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http://creativecommons.org/
licenses/by/4.0/.
© Crown 2020
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14919-4
10 NATURE COMMUNICATIONS |         (2020) 11:1091 | https://doi.org/10.1038/s41467-020-14919-4 | www.nature.com/naturecommunications
